Breaking News Instant updates and real-time market news.

GLPG

Galapagos

$114.88

0.61 (0.53%)

, MOR

MorphoSys

$24.78

0.7 (2.91%)

16:06
04/23/19
04/23
16:06
04/23/19
16:06

Galapagos NV, MorphoSys and Novartis announce GECKO study initiation

Galapagos NV (GLPG), MorphoSys (MOR) and Novartis (NVS) announced the initiation of GECKO, a Phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis. The GECKO trial aims to randomize 60 patients who receive either a dose of MOR106 or placebo subcutaneously for eight weeks, together with topical steroids, with a 16 week follow-up period. The primary endpoint of GECKO is the incidence of treatment emergent adverse and serious adverse events through day 169. Pharmacokinetics and occurrence of anti-drug-antibodies after subcutaneous administration of MOR106 will be assessed as secondary endpoints. In addition, the efficacy of MOR106 will be explored. Recruitment will take place in the U.S. and Canada, and the study is intended to serve as an investigational new drug opener with the FDA.

GLPG

Galapagos

$114.88

0.61 (0.53%)

MOR

MorphoSys

$24.78

0.7 (2.91%)

NVS

Novartis

$76.01

0.585 (0.78%)

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 26

    Apr

  • 28

    Apr

  • 04

    May

  • 08

    May

  • 08

    May

  • 23

    May

  • 31

    May

  • 20

    Jun

GLPG Galapagos
$114.88

0.61 (0.53%)

03/28/19
HCWC
03/28/19
INITIATION
Target $136
HCWC
Buy
Galapagos NV initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay started Galapagos NV with a Buy rating and $136 price target. The analyst think the company's pipeline in inflammatory and autoimmune diseases are likely to mature over the next 12 to 18 months and offer "key inflection points for the stock." He sees "meaningful upside over a filgotinib-centric valuation argument."
03/26/19
WBLR
03/26/19
UPGRADE
WBLR
Outperform
William Blair upgrades Vertex to Outperform after 'subpar' competitor data
William Blair analyst Y. Katherine Xu upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform on expectations the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. Proteostasis' triplet efficacy falls short of the high bar set by the Vertex triples, Xu tells investors in a research note. While Proteostasis is starting a Phase II study of the triplet that would include a higher PTI-808 dose and test a longer duration aiming to optimize response with data out around year-end 2019, the chance of it matching or exceeding Vertex triple efficacy is "very low," contends the analyst. With both Galapagos (GLPG)/AbbVie (ABB) and Proteostasis having shown "subpar data," Xu is upgrading Vertex shares to Outperform and raised her fair value estimate for the shares to $222 from $178. The analyst maintains her high probability of success of a Vertex triple combo reaching the cystic fibrosis market at 90% and ascribe peak sales of $10.2B, up from $8.9 billion previously.
02/26/19
LEHM
02/26/19
NO CHANGE
LEHM
Galapagos weakness could be tied to Pfizer safety alert, says Barclays
Barclays believes the weakness today in Galapagos NV (GLPG) could be attributed to, at least in part, the FDA's safety communication on Pfizer's (PFE) post-marketing study of 10mg daily Xeljanz. Competitor safety issues with higher dose JAK inhibitors was a major focus of Galapagos' post-earnings conference call last week, Barclays tells investors in a research note. Galapagos management, while limited in what it can say pending the data, seems to believe they can get both doses approved, Barclays contends. Further, the firm points out that the company has received no communication and sees no reason to conclude that the FDA has determined that thromboembolic events are a class effect of the JAKs. Shares of Galapagos are down 1.5%, or $1.45, to $97.28 in late morning trading.
03/29/19
HCWC
03/29/19
NO CHANGE
Target $150
HCWC
Buy
Galapagos NV price target raised to $150 from $136 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay raised his price target for Galapagos NV to $150 from $136 saying the data from the Phase 3 Finch 1 and 3 programs "did not disappoint." The filgotinib efficacy looks compelling and comparable to upadacitinib, despite the high placebo responses in the Finch program, Chattopadhyay tells investors in a research note. Importantly, the safety profile of filgotinib "differentiated itself from the pack," adds the analyst. He expects shares of Galapagos NV to outperform over the remainder of the year and keeps a Buy rating on the name.
MOR MorphoSys
$24.78

0.7 (2.91%)

04/02/19
BREN
04/02/19
UPGRADE
BREN
Buy
MorphoSys upgraded to Buy from Hold at Berenberg
01/28/19
PIPR
01/28/19
NO CHANGE
Target $38
PIPR
Overweight
MorphoSys weakness on patent ruling a buying opportunity, says Piper Jaffray
MorphoSys (MOR) shares are indicating down 5% this morning after the U.S. District Court sided against the company and ruled three of its patents invalid in a summary judgement of its lawsuit against Johnson & Johnson's (JNJ) Janssen this weekend, Piper Jaffray analyst Danielle Brill tells investors in a research note. The analyst is not surprised by the outcome and had low expectations for MorphoSys winning the case. The invalidated patents do not impact MorphoSys' drug MOR-202, and "very little has been lost" for the company, Brill writes. As such, she recommends buying the stock on today's weakness. The analyst keeps an Overweight rating on MorphoSys with a $38 price target.
02/27/19
PIPR
02/27/19
NO CHANGE
Target $38
PIPR
Overweight
Piper Jaffray more confident on MorphoSys receiving approval for MOR-208
Piper Jaffray analyst Danielle Brill kept her Overweight rating and $38 price target on MorphoSys after hosting meetings with its management. The analyst says the discussions added to her confidence that the company's MOR-208 will be approved in the U.S. for the treatment of refractory diffuse large b-cell lymphoma by mid-2020. Brill also maintains her view that MorphoSys is "substantially undervalued" given the "sizable commercial opportunity and the proximity to potential launch".
02/19/19
PIPR
02/19/19
NO CHANGE
Target $38
PIPR
Overweight
MorphoSys should be bought on CEO retirement weakness, says Piper Jaffray
After catching up with the company, Piper Jaffray analyst Danielle Brill says all of MorphoSys' operations are reportedly unaffected and FDA discussions for MOR208 remain on track. As such, the analyst does not see "anything negative to read into" with the news of CEO Simon Maroney's plans to retire. Brill still anticipates a MOR208 Biologics License Application filing via accelerated pathway by the second half of 2019 with approval in the first half of 2020. The analyst recommends buying shares of MorphoSys on today's weakness and keeps an Overweight rating on the name with a $38 price target. The stock in midday trading is down 59c to $26.86.
NVS Novartis
$76.01

0.585 (0.78%)

04/17/19
JEFF
04/17/19
NO CHANGE
Target $343
JEFF
Hold
Regeneron price target lowered to $343 from $376 at Jefferies
Jefferies analyst Biren Amin lowered his price target for Regeneron Pharmaceuticals (REGN) to $343 from $376 after doctors in his firm's survey viewed Novartis' (NVS) brolucizumab favorably. Retina specialists are particularly eager to prescribe brolucizumab, Amin tells investors in a research note. "Conservatively" incorporating the doctor estimates for brolucizumab uptake cuts revenue for Regeneron's Eylea in wet age-related macular degeneration by 13% over next two years, says the analyst. His revised Eylea estimates are now 4%-7% below consensus for fiscal 2020 through 2023. Amin thinks the Street underestimates the impact of the brolucizumab entry, which he thinks could "replicate events seen when Eylea launched and encroached on Lucentis share." The analyst keeps a Hold rating on Regeneron.
04/10/19
04/10/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Reduce from Hold at HSBC with analyst Erwan Rambourg saying the returns from Apple's recent announcements, including the Apple News+ premium news subscription, the Apple Card in partnership with Goldman Sachs (GS), Apple Arcade games as part of the App store and video subscription Apple TV+, could "take some time to extract." 2. AmerisourceBergen (ABC) downgraded to In Line from Outperform at Evercore ISI with analyst Michael Cherry citing group profit questions, lack of clarity with PharMEDium, and a reduction in multiple for peers Cardinal Health (CAH) and McKesson (MCK). 3. Novartis (NVS) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Mark Purcell saying the spinoff of Alcon will put more attention on the generics risk Novartis faces in its pharma business. 4. TerraForm Power (TERP) downgraded to Sell from Neutral at Goldman Sachs with analyst Brian Lee saying that while the company is in the midst of an operational transition that may improve cash flow and dividend flexibility, the upside appears to be priced in. 5. Foot Locker (FL) assumed with a Neutral from Buy at Citi with analyst Paul Lejuez saying while Foot Locker has "tailwinds at its back" in North America with comps inflecting positively in Q4, the company still faces many of the same headwinds as other specialty retailers given its "significant" mall exposure and EBIT pressure from direct-to-consumer. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/10/19
MSCO
04/10/19
INITIATION
Target $65
MSCO
Overweight
Alcon initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst David Lewis initiated Alcon (ALC) with an Overweight rating and $65 price target, stating that he expects its pipeline, sales and capex reinvestment to drive an inflection in revenue growth and margin expansion post the spinoff from Novartis (NVS). Near-term improvement at Alcon hinges on the two key PanOptix and PRECISION1 franchises, Lewis noted.
04/10/19
MZHO
04/10/19
NO CHANGE
Target $41
MZHO
Buy
Alcon spinoff shows Bausch Health is undervalued, says Mizuho
Mizuho analyst Irina Koffler reiterates a Buy rating on Bausch Health Companies (BHC) with a $41 price target following Novartis' (NVS) spinoff of Alcon (ALC). Bausch's smaller B+L segment should trade at a "slight discount" to market leader Alcon, but calculate that the market is currently assigning only a 13 times 2019 enterprise value to EBITA multiple to the B+L business, Koffler tells investors in a research note. This highlights that Bausch Health is undervalued, contends the analyst.

TODAY'S FREE FLY STORIES

LGF.B

Lionsgate

$9.84

-0.375 (-3.67%)

, LGF.A

Lionsgate

$10.37

-0.43 (-3.98%)

19:38
08/25/19
08/25
19:38
08/25/19
19:38
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

LGF.B

Lionsgate

$9.84

-0.375 (-3.67%)

LGF.A

Lionsgate

$10.37

-0.43 (-3.98%)

ROKU

Roku

$137.77

-1.35 (-0.97%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$42.47

-1.29 (-2.95%)

NFLX

Netflix

$291.40

-5.47 (-1.84%)

AAPL

Apple

$202.73

-9.82 (-4.62%)

TGT

Target

$103.64

-2.62 (-2.47%)

DIS

Disney

$131.70

-4.37 (-3.21%)

NSRGY

Nestle

$0.00

(0.00%)

ULTA

Ulta Beauty

$322.34

-12.5 (-3.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 29

    Aug

  • 04

    Sep

  • 05

    Sep

  • 15

    Sep

  • 19

    Sep

  • 23

    Sep

  • 25

    Sep

  • 27

    Oct

T

AT&T

$34.82

-0.57 (-1.61%)

, CMCSA

Comcast

$42.47

-1.29 (-2.95%)

18:38
08/25/19
08/25
18:38
08/25/19
18:38
On The Fly
Box Office Battle: 'Angel has Fallen' wins weekend with $21.3M debut »

"Box Office Battle" is…

T

AT&T

$34.82

-0.57 (-1.61%)

CMCSA

Comcast

$42.47

-1.29 (-2.95%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$53.75

-1.03 (-1.88%)

LGF.A

Lionsgate

$10.37

-0.43 (-3.98%)

LGF.B

Lionsgate

$9.84

-0.375 (-3.67%)

DIS

Disney

$131.70

-4.37 (-3.21%)

VIAB

Viacom

$24.65

-1.21 (-4.68%)

VIA

Viacom

$26.85

-0.74 (-2.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 05

    Sep

  • 10

    Sep

  • 11

    Sep

  • 23

    Oct

  • 27

    Oct

FB

Facebook

$177.69

-4.39 (-2.41%)

17:23
08/25/19
08/25
17:23
08/25/19
17:23
Periodicals
U.S. lawmaker still concerned about Facebook cryptocurrency, Reuters reports »

The chair of the U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

FCX

Freeport McMoRan

$8.84

-0.295 (-3.23%)

, BHP

BHP Group

$46.72

-0.52 (-1.10%)

17:11
08/25/19
08/25
17:11
08/25/19
17:11
Periodicals
China to raise tariffs on U.S. scrap copper, aluminum from Dec. 15, Reuters says »

China will impose an…

FCX

Freeport McMoRan

$8.84

-0.295 (-3.23%)

BHP

BHP Group

$46.72

-0.52 (-1.10%)

SCCO

Southern Copper

$29.56

-0.61 (-2.02%)

RIO

Rio Tinto

$47.99

-0.56 (-1.15%)

AA

Alcoa

$17.47

-0.57 (-3.16%)

ARNC

Arconic

$24.32

-0.77 (-3.07%)

KALU

Kaiser Aluminum

$86.11

-3.97 (-4.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 16

    Oct

SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

, SPX

S&P 500

$0.00

(0.00%)

17:01
08/25/19
08/25
17:01
08/25/19
17:01
Periodicals
China warns of consequences if U.S. continues 'wrong actions,' Reuters says »

China said it strongly…

SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$211.38

-10.69 (-4.81%)

16:51
08/25/19
08/25
16:51
08/25/19
16:51
Periodicals
Tesla scouting sites for possible factory in Germany, Reuters reports »

Tesla is scouting out…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 23

    Sep

ESLOY

EssilorLuxottica

$0.00

(0.00%)

, NSRGY

Nestle

$0.00

(0.00%)

16:48
08/25/19
08/25
16:48
08/25/19
16:48
Periodicals
Third Point builds stake in EssilorLuxottica, Reuters reports »

Third Point, the U.S.…

ESLOY

EssilorLuxottica

$0.00

(0.00%)

NSRGY

Nestle

$0.00

(0.00%)

CPB

Campbell Soup

$42.66

-1.01 (-2.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

  • 01

    Oct

SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

, SPX

S&P 500

$0.00

(0.00%)

16:41
08/25/19
08/25
16:41
08/25/19
16:41
Periodicals
Trump adviser not expecting China to retaliated against latest tariffs, Reuters »

White House economic…

SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

, SPX

S&P 500

$0.00

(0.00%)

16:33
08/25/19
08/25
16:33
08/25/19
16:33
Periodicals
Leaders says U.S., Japan have agreed in principle on trade deal, Reuters says »

The U.S. and Japan agreed…

SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

, SPX

S&P 500

$0.00

(0.00%)

16:30
08/25/19
08/25
16:30
08/25/19
16:30
Periodicals
Trump regrets not raising tariffs on China higher, Reuters reports »

President Donald Trump…

SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$131.70

-4.37 (-3.21%)

, TGT

Target

$103.64

-2.62 (-2.47%)

16:16
08/25/19
08/25
16:16
08/25/19
16:16
Hot Stocks
Disney, Target team up to bring Disney store to retailer shoppers »

Disney (DIS) and Target…

DIS

Disney

$131.70

-4.37 (-3.21%)

TGT

Target

$103.64

-2.62 (-2.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

SEDG

SolarEdge

$80.96

-1.14 (-1.39%)

16:11
08/25/19
08/25
16:11
08/25/19
16:11
Hot Stocks
SolarEdge announces death of co-chairman, founder Guy Sella »

SolarEdge Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$45.12

-1.92 (-4.08%)

, AMD

AMD

$29.55

-2.35 (-7.37%)

04:55
08/25/19
08/25
04:55
08/25/19
04:55
Conference/Events
MUFG Securities to hold a tour »

MUFG Securities Tech Tour…

AMAT

Applied Materials

$45.12

-1.92 (-4.08%)

AMD

AMD

$29.55

-2.35 (-7.37%)

ANET

Arista Networks

$223.35

-3.84 (-1.69%)

CHKP

Check Point

$106.84

-2.36 (-2.16%)

CSCO

Cisco

$46.65

-1.55 (-3.22%)

EQIX

Equinix

$549.81

-4.27 (-0.77%)

FLEX

Flex

$9.72

-0.54 (-5.26%)

INTC

Intel

$44.97

-1.79 (-3.83%)

NVDA

Nvidia

$162.51

-8.93 (-5.21%)

OTEX

OpenText

$38.54

-0.57 (-1.46%)

PYPL

PayPal

$106.08

-2.66 (-2.45%)

RNG

RingCentral

$141.50

-0.86 (-0.60%)

SQ

Square

$61.65

-3 (-4.64%)

STX

Seagate

$46.96

-0.62 (-1.30%)

TWLO

Twilio

$127.90

-2.585 (-1.98%)

V

Visa

$175.24

-4.91 (-2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

  • 28

    Aug

  • 29

    Aug

  • 05

    Sep

  • 06

    Sep

  • 09

    Sep

  • 10

    Sep

  • 16

    Sep

  • 17

    Sep

  • 18

    Sep

  • 19

    Sep

  • 10

    Oct

  • 15

    Oct

  • 24

    Oct

  • 27

    Oct

  • 06

    Nov

  • 13

    Nov

  • 13

    Nov

  • 12

    Dec

  • 16

    Dec

NFLX

Netflix

$291.40

-5.47 (-1.84%)

, DIS

Disney

$131.70

-4.37 (-3.21%)

11:55
08/24/19
08/24
11:55
08/24/19
11:55
Periodicals
Football season is back, key moment for TV future, Barron's says »

On Sept. 5, when the…

NFLX

Netflix

$291.40

-5.47 (-1.84%)

DIS

Disney

$131.70

-4.37 (-3.21%)

FOXA

Fox Corp.

$31.76

-1.29 (-3.90%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$42.47

-1.29 (-2.95%)

CBS

CBS

$41.39

-2.06 (-4.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 23

    Sep

  • 27

    Oct

AAPL

Apple

$202.73

-9.82 (-4.62%)

, AMZN

Amazon.com

$1,752.00

-52 (-2.88%)

09:03
08/24/19
08/24
09:03
08/24/19
09:03
Periodicals
Costco the most 'woke' company out there, Barron's says »

Earlier this week, the…

AAPL

Apple

$202.73

-9.82 (-4.62%)

AMZN

Amazon.com

$1,752.00

-52 (-2.88%)

BLK

BlackRock

$407.29

-11.55 (-2.76%)

WMT

Walmart

$110.83

-1.07 (-0.96%)

COST

Costco

$274.16

-5.7 (-2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 25

    Sep

  • 03

    Oct

  • 27

    Oct

  • 13

    Nov

  • 14

    Nov

MMM

3M

$155.84

-5.04 (-3.13%)

08:58
08/24/19
08/24
08:58
08/24/19
08:58
Periodicals
3M stock still not looking like a bargain, Barron's says »

3M shares are down by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ULTA

Ulta Beauty

$322.34

-12.5 (-3.73%)

08:56
08/24/19
08/24
08:56
08/24/19
08:56
Periodicals
Ulta Beauty bucking downbeat retail trends, Barron's says »

Ulta Beauty has been one…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 25

    Sep

CMCSK

Comcast

$0.00

(0.00%)

, CMCSA

Comcast

$42.47

-1.29 (-2.95%)

08:49
08/24/19
08/24
08:49
08/24/19
08:49
Periodicals
Roku working for investors, Barron's says »

The streaming war…

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$42.47

-1.29 (-2.95%)

DIS

Disney

$131.70

-4.37 (-3.21%)

NFLX

Netflix

$291.40

-5.47 (-1.84%)

AAPL

Apple

$202.73

-9.82 (-4.62%)

ROKU

Roku

$137.77

-1.35 (-0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 05

    Sep

  • 23

    Sep

  • 27

    Oct

NSRGY

Nestle

$0.00

(0.00%)

08:44
08/24/19
08/24
08:44
08/24/19
08:44
Periodicals
Nestle stock looking appetizing after big gain, Barron's says »

Nestle is having a great…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$291.40

-5.47 (-1.84%)

, DIS

Disney

$131.70

-4.37 (-3.21%)

08:39
08/24/19
08/24
08:39
08/24/19
08:39
Periodicals
Football season is back, key moment for TV future, Barron's says »

On Sept. 5, when the…

NFLX

Netflix

$291.40

-5.47 (-1.84%)

DIS

Disney

$131.70

-4.37 (-3.21%)

FOXA

Fox Corp.

$31.76

-1.29 (-3.90%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$42.47

-1.29 (-2.95%)

CBS

CBS

$41.39

-2.06 (-4.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 23

    Sep

  • 27

    Oct

AMZN

Amazon.com

$1,752.00

-52 (-2.88%)

, FDX

FedEx

$151.94

-6.17 (-3.90%)

08:05
08/24/19
08/24
08:05
08/24/19
08:05
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,752.00

-52 (-2.88%)

FDX

FedEx

$151.94

-6.17 (-3.90%)

UPS

UPS

$111.29

-3.91 (-3.39%)

F

Ford

$8.76

-0.27 (-2.99%)

GM

General Motors

$36.06

-1.19 (-3.19%)

DDAIF

Daimler AG

$0.00

(0.00%)

HMC

Honda

$22.90

-0.32 (-1.38%)

TM

Toyota

$127.94

-1.69 (-1.30%)

VWAGY

Volkswagen

$0.00

(0.00%)

AAPL

Apple

$202.73

-9.82 (-4.62%)

FB

Facebook

$177.69

-4.39 (-2.41%)

TWTR

Twitter

$41.01

-1.16 (-2.75%)

GOOGL

Alphabet Class A

$1,154.66

-35.75 (-3.00%)

GOOG

Alphabet

$1,151.72

-36.81 (-3.10%)

ADM

Archer Daniels

$37.44

-0.48 (-1.27%)

REGI

Renewable Energy

$11.65

0.61 (5.53%)

GPRE

Green Plains

$7.34

-0.68 (-8.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 15

    Sep

  • 17

    Sep

  • 17

    Sep

  • 18

    Sep

  • 19

    Sep

  • 23

    Sep

  • 24

    Sep

  • 23

    Oct

  • 23

    Oct

  • 27

    Oct

  • 13

    Nov

AMAT

Applied Materials

$45.12

-1.92 (-4.08%)

, AMD

AMD

$29.55

-2.35 (-7.37%)

04:55
08/24/19
08/24
04:55
08/24/19
04:55
Conference/Events
MUFG Securities to hold a tour »

MUFG Securities Tech Tour…

AMAT

Applied Materials

$45.12

-1.92 (-4.08%)

AMD

AMD

$29.55

-2.35 (-7.37%)

ANET

Arista Networks

$223.35

-3.84 (-1.69%)

CHKP

Check Point

$106.84

-2.36 (-2.16%)

CSCO

Cisco

$46.65

-1.55 (-3.22%)

EQIX

Equinix

$549.81

-4.27 (-0.77%)

FLEX

Flex

$9.72

-0.54 (-5.26%)

INTC

Intel

$44.97

-1.79 (-3.83%)

NVDA

Nvidia

$162.51

-8.93 (-5.21%)

OTEX

OpenText

$38.54

-0.57 (-1.46%)

PYPL

PayPal

$106.08

-2.66 (-2.45%)

RNG

RingCentral

$141.50

-0.86 (-0.60%)

SQ

Square

$61.65

-3 (-4.64%)

STX

Seagate

$46.96

-0.62 (-1.30%)

TWLO

Twilio

$127.90

-2.585 (-1.98%)

V

Visa

$175.24

-4.91 (-2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

  • 28

    Aug

  • 29

    Aug

  • 05

    Sep

  • 06

    Sep

  • 09

    Sep

  • 10

    Sep

  • 16

    Sep

  • 17

    Sep

  • 18

    Sep

  • 19

    Sep

  • 10

    Oct

  • 15

    Oct

  • 24

    Oct

  • 27

    Oct

  • 06

    Nov

  • 13

    Nov

  • 13

    Nov

  • 12

    Dec

  • 16

    Dec

DB

Deutsche Bank

$6.98

-0.19 (-2.65%)

, COF

Capital One

$83.06

-2.68 (-3.13%)

17:57
08/23/19
08/23
17:57
08/23/19
17:57
Periodicals
Deutsche Bank, Capital One won't say if they have Trump's tax returns, NYP says »

Deutsche Bank (DB) and…

DB

Deutsche Bank

$6.98

-0.19 (-2.65%)

COF

Capital One

$83.06

-2.68 (-3.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

MXIM

Maxim Integrated

$52.14

-2.42 (-4.44%)

17:53
08/23/19
08/23
17:53
08/23/19
17:53
Hot Stocks
Maxim Integrated's Jain sells 12,683 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

GLD

SPDR Gold Shares

$144.15

2.77 (1.96%)

17:42
08/23/19
08/23
17:42
08/23/19
17:42
Hot Stocks
SPDR Gold Shares holdings rise to 859.83MT to 854.84MT »

This is the fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.